CTOs on the Move

Morningside Manor Inc

www.morningsidemin.org

 
Morningside Ministries was created with the specific mission of caring for those who cared for us. The ministry was founded in 1961 by the Southwest Texas Conference of the United Methodist Church and joined five years later by First Presbyterian Church
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Witham Health Services

Witham Health Services is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Witham Health Services is based in Lebanon, IN. You can find more information on Witham Health Services at www.witham.org

Access Health CT

Access Health CT is bringing the benefits of Health Care Reform to Connecticut. As the state`s official health insurance marketplace, we`re making it easier and more affordable for individuals, families, and small businesses to get quality health care coverage.

Lark

Lark Health is the leading virtual chronic disease management and prevention platform. Lark helps people stay healthy and in control of their conditions, such as Diabetes, Prediabetes, Cardiovascular Disease, and Anxiety from the comfort of their homes.

COREBIO GROUP

COREBIO GROUP is a Belmont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Foghorn Therapeutics

More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.